RxDoctor Payments Data

Thomas Strinden, MD

Ophthalmology · Fargo, NDNPI 1841212404

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,254 of the $2,805 with a category attached, or 80.3%. Alcon accounts for 92.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $2,221 and has fallen 82.0% since, to $400 in 2025.

$2,805in general payments, 2019–2025

Across 24 payments — averaging $116.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Rxsight Inc$102
  • The Cameron-ehlen Group, Inc.$53
  • Omeros Corporation$42
  • Rayner Intraocular Lenses Limited$14
$20,776in research payments, 2019–2025

Across 2 payments — averaging $10,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$21K

What the payments were for

  • Speaking & faculty fees$261%
  • Travel & lodging$2,25480%
  • Food & beverage$52619%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon13$2,594
Rxsight Inc4$102
The Cameron-ehlen Group, Inc.3$53
Omeros Corporation3$42
Rayner Intraocular Lenses Limited1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,805 in reported general payments places this provider in the 80th percentile of 41 ophthalmology providers in North Dakota.

See all ophthalmology providers in North Dakota

Medicare billing

Part B allowed, 2024
$246,397
Medicare patients
601
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine53$51,622
LumiganBimatoprost56$20,601
RocklatanNetarsudil Mesylat/Latanoprost17$10,421
Travoprost43$8,354
SimbrinzaBrinzolamide/Brimonidine Tart33$6,721
Cyclosporine13$5,638
VyzultaLatanoprostene Bunod13$4,548
CombiganBrimonidine Tartrate/Timolol17$4,352
Alphagan PBrimonidine Tartrate14$4,072
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$4,026
Latanoprost190$3,006
Prednisolone Acetate42$1,502
Brimonidine Tartrate15$1,021
Doxycycline Hyclate31$1,020
Timolol Maleate82$925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$2,594$6,72133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 41 ophthalmology providers in North Dakota.

Other ophthalmology in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →